Research programme: diabetes/obesity therapy - Celera Genomics
Latest Information Update: 04 Oct 2006
At a glance
- Originator Celera Genomics Group
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Diabetes mellitus; Obesity
Most Recent Events
- 25 Jan 2006 Discontinued - Preclinical for Diabetes mellitus in USA (unspecified route)
- 25 Jan 2006 Discontinued - Preclinical for Obesity in USA (unspecified route)
- 02 Nov 2005 The programme is available for partnership (http://www.celera.com)